Depressive symptoms during buprenorphine vs. methadone maintenance: Findings from a randomised, controlled trial in opioid dependence

Dean, Angela J.; Bell, James; Christie, Macdonald J.; Mattick, Richard P.

doi:10.1016/j.eurpsy.2004.09.002

Cited by 78Opioid Use Disorder TreatmentSubstance Abuse Treatment and OutcomesTreatment of Major Depression

Depressive symptoms during buprenorphine vs. methadone maintenance: Findings from a randomised, controlled trial in opioid dependence

Dean, Angela J., Bell, James, Christie, Macdonald J., Mattick, Richard P.·2004·European Psychiatry

DOI 10.1016/j.eurpsy.2004.09.002

Open this paper in CoChat — free account

Abstract

Research suggests that buprenorphine may possess antidepressant activity. The Beck Depression Inventory was completed at baseline and 3 months by heroin dependent subjects receiving either buprenorphine or methadone maintenance as part of a larger, pre-existing, double blind trial conducted by NDARC (Australia). Depressive symptoms improved in all subjects, with no difference between methadone and buprenorphine groups, suggesting no differential benefit on depressive symptoms for buprenorphine compared to methadone.

Integrity signals

Registry

Crossref · 10.1016/j.eurpsy.2004.09.002

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Three additional studies investigating the course of depressive symptoms in opiate dependence patients treated with buprenorphine included a total of 248 patients.
“Three additional studies investigating the course of depressive symptoms in opiate dependence patients treated with BUP were also considered in addition to the Striebel case (a total of 248 patients) [48,49,50].”
From The Efficacy of Buprenorphine in Major Depression, Treatment-Resistant Depression and Suicidal Behavior: A Systematic Review (2018) · cites this paper as [49]
Dean et al. reported improvements in depressive symptoms in all heroin-dependent patients comparing buprenorphine and methadone treatments, with no significant differences between the groups.
“Dean and colleagues [49], comparing BUP and methadone treatments on a group of heroin-dependent patients, reported improvements in depressive symptoms in all subjects, with no significant differences between the groups.”
From The Efficacy of Buprenorphine in Major Depression, Treatment-Resistant Depression and Suicidal Behavior: A Systematic Review (2018) · cites this paper as [49]
Many studies have proposed treatment with buprenorphine in augmentation with standard antidepressants such as SSRIs or SNRIs, or with other drugs such as antipsychotics, benzodiazepines, and mood stabilizers.
“Many studies [44,45,49,50,51] proposed the treatment with BUP in augmentation with standard antidepressants such as SSRIs or SNRIs (or with other drugs, such as antipsychotics, benzodiazepines, and mood stabilizers [51,52] with which the patient was usually being treated).”
From The Efficacy of Buprenorphine in Major Depression, Treatment-Resistant Depression and Suicidal Behavior: A Systematic Review (2018) · cites this paper as [49]

An inventory for measuring depression
BECK, A. T. (1961) · Archives of General Psychiatry · doi:10.1001/archpsyc.1961.01710120031004 · Cited by 38,032 · see citing works
The Effectiveness of Methadone Maintenance Treatment: Patients, Programs, Services, and Outcome
Ball, J. C., & Ross, A. O. (1991) · Cited by 903 · see citing works
Antidepressant-Like Effects of κ-Opioid Receptor Antagonists in the Forced Swim Test in Rats
Mague, S. D., Pliakas, A. M., Todtenkopf, M. S., Tomasiewicz, H. C., Zhang, Y., Stevens, W. C., Jones, R. M., Portoghese, P. S., & Carlezon, W. A. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.046433 · Cited by 485 · see citing works
Development and validation of a multi-dimensional instrument for assessing outcome of treatment among opiate users: the Opiate Treatment Index.
Darke, S., Hall, W., Wodak, A., Heather, N., & Ward, J. (1992) · British Journal of Addiction · doi:10.1111/j.1360-0443.1992.tb02719.x · Cited by 485 · see citing works
Diagnosis and Symptoms of Depression in Opiate Addicts
Rounsaville, B. J. (1982) · Archives of General Psychiatry · doi:10.1001/archpsyc.1982.04290020021004 · Cited by 415 · see citing works
Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial
Ling, W., Charuvastra, C., Collins, J. F., Batki, S., Brown, L. S., Kintaudi, P., Wesson, D. R., Mcnicholas, L., Tusel, D. J., Malkerneker, U., et al. (1998) · Addiction · doi:10.1046/j.1360-0443.1998.9344753.x · Cited by 402 · see citing works
Buprenorphine Treatment of Refractory Depression
Bodkin, J. A., Zornberg, G. L., Lukas, S. E., & Cole, J. O. (1995) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199502000-00008 · Cited by 346 · see citing works
Comparison of Pharmacological Activities of Buprenorphine and Norbuprenorphine: Norbuprenorphine Is a Potent Opioid Agonist
Huang, P., Kehner, G. B., Cowan, A., & Liu‐Chen, L. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29586-0 · Cited by 340 · see citing works
Buprenorphine versus methadone maintenance therapy: a randomized double‐blind trial with 405 opioid‐dependent patients
Mattick, R. P., Ali, R. L., White, J. M., O’Brien, S., Wolk, S., & Danz, C. (2003) · Addiction · doi:10.1046/j.1360-0443.2003.00335.x · Cited by 284 · see citing works
Possible antidepressive effects of opioids: Action of buprenorphine
Emrich, H. M., Vogt, P., & Herz, A. (1982) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1982.tb39483.x · Cited by 152 · see citing works
Buprenorphine: a controlled clinical trial in the treatment of opioid dependence
Pani, P., Maremmani, I., Pirastu, R., Tagliamonte, A., & Gessa, G. L. (2000) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(99)00140-4 · Cited by 149 · see citing works
Implication of endogenous opioid system in the learned helplessness model of depression
Tejedor‐Real, P., Micó, J. A., Maldonado, R. J., Roques, B. P., & Gibert‐Rahola, J. (1995) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(95)00067-7 · Cited by 119 · see citing works
Differential effects of buprenorphine and morphine on immune and neuroendocrine functions following acute administration in the rat mesencephalon periaqueductal gray
Gomez‐Flores, R., & Weber, R. J. (2000) · Immunopharmacology · doi:10.1016/s0162-3109(00)00198-3 · Cited by 118 · see citing works
Early Treatment Time Course of Depressive Symptoms in Opiate Addicts
Strain, E. C., Stitzer, M. L., & Bigelow, G. E. (1991) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-199104000-00007 · Cited by 112 · see citing works
An open-label study of a functional opioid κ antagonist in the treatment of opioid dependence
Rothman, R. B. (2000) · Journal of Substance Abuse Treatment · doi:10.1016/s0740-5472(99)00074-4 · Cited by 112 · see citing works
Depressive symptoms during buprenorphine treatment of opioid abusers
Kosten, T. R., Morgan, C., & Kosten, T. A. (1990) · Journal of Substance Abuse Treatment · doi:10.1016/0740-5472(90)90035-o · Cited by 110 · see citing works
Pharmacokinetics and Subjective Effects of Sublingual Buprenorphine, Alone or in Combination with Naloxone
Harris, D. S., Mendelson, J. E., Lin, E. T., Upton, R. A., & Jones, R. T. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443050-00005 · Cited by 87 · see citing works
Modulation of 5‐hydroxytryptamine efflux from rat cortical synaptosomes by opioids and nociceptin
Sbrenna, S., Marti, M., Morari, M., Calò, G., Guerrini, R., Beani, L., & Bianchi, C. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703321 · Cited by 71 · see citing works
The use of antidepressants among injecting drug users in Sydney, Australia
Darke, S. G., & Ross, J. E. (2000) · Addiction · doi:10.1046/j.1360-0443.2000.95340711.x · Cited by 53 · see citing works
METHADONE INHIBITION OF 3H-5-HYDROXYTRYPTAMINE UPTAKE BY SYNAPTOSOMES
Ciofalo, F. R. (1974) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)29811-1 · Cited by 43 · see citing works
The Pathophysiologies of Substance Abuse and Affective Disorders
STEVEN, C. D. (1987) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198702000-00002 · Cited by 42 · see citing works
Comparing Opiate Users in Methadone Treatment with Untreated Opiate Users: Results of a Follow-up Study with a Toronto Opiate User Cohort
Fischer, B., Gliksman, L., Rehm, J. T., Daniel, N., & Medved, W. (1999) · Canadian Journal of Public Health · doi:10.1007/bf03404513 · Cited by 33 · see citing works
A comparison of four buprenorphine dosing regimens using open‐dosing procedures: is twice‐weekly dosing possible?
Petry, N. M., Bickel, W. K., & Badger, G. J. (2000) · Addiction · doi:10.1046/j.1360-0443.2000.95710698.x · Cited by 25 · see citing works
Possible antidepressant activity of methadone
Montis, M. G. D., Devoto, P., & Tagliamonte, A. (1982) · European Journal of Pharmacology · doi:10.1016/0014-2999(82)90587-8 · Cited by 6 · see citing works
Treatment Success: Association With Patient Baseline, Program Elements, and In-treatment Process
Ball, J. C., & Ross, A. (1991) · Springer eBooks · doi:10.1007/978-1-4613-9089-3_11 · Cited by 3 · see citing works
Methadone for depression.
Goldstein, J. A. (1984) · PubMed · Cited by 2 · see citing works

Flagged first, then by citations

3 of the 29 references couldn’t be matched to a known paper.

Sorted by citations

Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation
Connock, M. J., Juarez-Garcia, A., Jowett, S. M., Frew, E. J., Liu, Z., Taylor, R. S., Fry-Smith, A., Day, E., Lintzeris, N., Roberts, T. E., et al. (2007) · Health Technology Assessment · doi:10.3310/hta11090 · Cited by 580 · see citing works
BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP
Lingford-Hughes, A., Welch, S., Peters, L., Nutt, D., & With expert reviewers (in alphabetical order): Ball D, B. N. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112444324 · Cited by 332 · see citing works
Synthetic and Receptor Signaling Explorations of the Mitragyna Alkaloids: Mitragynine as an Atypical Molecular Framework for Opioid Receptor Modulators
Kruegel, A. C., Gassaway, M. M., Kapoor, A., Váradi, A., Majumdar, S., Filizola, M., Javitch, J. A., & Sameš, D. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b00360 · Cited by 325 · see citing works
The Kappa Opioid Receptor: From Addiction to Depression, and Back
Lalanne, L., Ayrancı, G., Kieffer, B. L., & Lutz, P.-É. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00170 · Cited by 227 · see citing works
Buprenorphine versus methadone for the treatment of opioid dependence: a systematic review and meta-analysis of randomised and observational studies
Degenhardt, L. J., Clark, B., Macpherson, G., Leppan, O., Nielsen, S., Zahra, E., Larance, B., Kimber, J., Martino-Burke, D., Hickman, M., et al. (2023) · The Lancet Psychiatry · doi:10.1016/s2215-0366(23)00095-0 · Cited by 180 · see citing works
The Efficacy of Buprenorphine in Major Depression, Treatment-Resistant Depression and Suicidal Behavior: A Systematic Review
Serafini, G., Adavastro, G., Canepa, G., De Berardis, D., Valchera, A., Pompili, M., Nasrallah, H., & Amore, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082410 · Cited by 162 · see citing works
Substance use and quality of life over 12 months among buprenorphine maintenance-treated and methadone maintenance-treated heroin-addicted patients
Maremmani, I., Pani, P. P., Pacini, M., & Perugi, G. (2007) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2006.11.009 · Cited by 159 · see citing works
Meta‐analysis of depression and substance use and impairment among intravenous drug users (IDUs)
Conner, K. R., Pinquart, M., & Duberstein, P. R. (2008) · Addiction · doi:10.1111/j.1360-0443.2007.02118.x · Cited by 151 · see citing works
Psychotherapeutic Benefits of Opioid Agonist Therapy
Tenore, P. L. (2008) · Journal of Addictive Diseases · doi:10.1080/10550880802122646 · Cited by 143 · see citing works
Depression among heroin users: 12-Month outcomes from the Australian Treatment Outcome Study (ATOS)
Havard, A., Teesson, M., Darke, S. G., & Ross, J. E. (2006) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2006.03.012 · Cited by 127 · see citing works
Patient characteristics associated with buprenorphine/naloxone treatment outcome for prescription opioid dependence: Results from a multisite study
Dreifuss, J. A., Griffin, M. L., Frost, K. H., Fitzmaurice, G. M., Potter, J. S., Fiellin, D. A., Selzer, J. A., Hatch‐Maillette, M. A., Sonne, S. C., & Weiss, R. D. (2013) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.12.010 · Cited by 122 · see citing works
The missing 'P' in pain management: how the current opioid epidemic highlights the need for psychiatric services in chronic pain care.
Howe, C., & Sullivan, M. (2014) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2013.10.003 · Cited by 107 · see citing works
Self-treatment: Illicit buprenorphine use by opioid-dependent treatment seekers
Schuman‐Olivier, Z., Albanese, M. A., Nelson, S. E., Roland, L., Puopolo, F., Klinker, L., & Shaffer, H. J. (2010) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2010.03.014 · Cited by 94 · see citing works
Buprenorphine treatment outcome in dually diagnosed heroin dependent patients: A retrospective study
Gerra, G., Leonardi, C., D'Amore, A., Strepparola, G., Fagetti, R., Assi, C., Zaimovic, A., & Lucchini, A. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.10.007 · Cited by 88 · see citing works
Buprenorphine in cancer pain
Davis, M. P. (2005) · Supportive Care in Cancer · doi:10.1007/s00520-005-0849-9 · Cited by 69 · see citing works
Patterns of major depression and drug-related problems amongst heroin users across 36 months
Darke, S. G., Mills, K. L., Teesson, M., Ross, J. E., Williamson, A., & Havard, A. (2009) · Psychiatry Research · doi:10.1016/j.psychres.2007.12.007 · Cited by 65 · see citing works
Buprenorphine Pharmacodynamics and Pharmacokinetics
WALSH, S. L., & Middleton, L. S. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6974-2_12 · Cited by 63 · see citing works
Equity of access to treatment, and barriers to treatment for illicit drug use in Australia
Digiusto, E., & Treloar, C. (2007) · Addiction · doi:10.1111/j.1360-0443.2007.01842.x · Cited by 65 · see citing works
Does naltrexone treatment lead to depression? Findings from a randomized controlled trial in subjects with opioid dependence
Dean, A. J., Saunders, J. B., Jones, R., Young, R. M., Connor, J. P., & Lawford, B. R. (2006) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0605 · Cited by 59 · see citing works
Prevalence of mood and substance use disorders among patients seeking primary care office-based buprenorphine/naloxone treatment
Savant, J. D., Barry, D. T., Cutter, C. J., Joy, M. T., Dinh, A., Schottenfeld, R. S., & Fiellin, D. A. (2012) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.06.020 · Cited by 52 · see citing works
Do methadone and buprenorphine have the same impact on psychopathological symptoms of heroin addicts?
Maremmani, A. G. I., Rovai, L., Pani, P., Pacini, M., Lamanna, F., Rugani, F., Schiavi, E., Dell’Osso, L., & Maremmani, I. (2011) · Annals of General Psychiatry · doi:10.1186/1744-859x-10-17 · Cited by 53 · see citing works
Drug & Alcohol Review
Saunders, J. B. (2004) · Cited by 52 · see citing works
Antidepressant treatment does not improve buprenorphine retention among opioid-dependent persons
Stein, M. D., Herman, D. S., Kettavong, M., Cioe, P. A., Friedmann, P. D., Tellioğlu, T., & Anderson, B. J. (2010) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2010.05.014 · Cited by 45 · see citing works
Effect of Psychiatric Severity on the Outcome of Methadone Maintenance Treatment
Pani, P. P., Maremmani, I., Pacini, M., Lamanna, F., Maremmani, A. G. I., & Dell’Osso, L. (2010) · European Addiction Research · doi:10.1159/000321465 · Cited by 43 · see citing works
Is residential treatment effective for opioid use disorders? A longitudinal comparison of treatment outcomes among opioid dependent, opioid misusing, and non-opioid using emerging adults with substance use disorder
Schuman‐Olivier, Z., Greene, M. C., Bergman, B. G., & Kelly, J. F. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2014.09.009 · Cited by 42 · see citing works
Hazardous alcohol consumption and other barriers to antiviral treatment among hepatitis C positive people receiving opioid maintenance treatment
WATSON, B., CONIGRAVE, K. M., WALLACE, C., WHITFIELD, J. B., WURST, F., & HABER, P. S. (2007) · Drug and Alcohol Review · doi:10.1080/09595230701247681 · Cited by 37 · see citing works
Depression and Outcomes of Methadone and Buprenorphine Treatment Among People with Opioid Use Disorders: A Literature Review
Ghabrash, M. F., Bahremand, A., Veilleux, M., Blais-Normandin, G., Chicoine, G., Sutra-Cole, C., Kaur, N., Ziegler, D., Dubreucq, S., Juteau, L.-C., et al. (2020) · Journal of Dual Diagnosis · doi:10.1080/15504263.2020.1726549 · Cited by 40 · see citing works
Impact of opioid agonist treatment on mental health in patients with opioid use disorder: a systematic review and network meta-analysis of randomized clinical trials
Zadeh, E. M., Ziafat, K., Yazdani, K., Kamel, M. M., Wong, J. S. H., Modabbernia, A., Blanken, P., Verthein, U., Schütz, C. G., Jang, K. L., et al. (2021) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2021.1887202 · Cited by 38 · see citing works
Buprenorphine/Naloxone for opioid dependence: clinical practice guideline.
Handford, C. D., Kahan, M., Srivastava, A., Cirone, S., & Palda, V. A. (2011) · Cited by 36 · see citing works
Pharmacological treatment for depression during opioid agonist treatment for opioid dependence
Pani, P. P., Vacca, R., Trogu, E., Amato, L., & Davoli, M. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008373.pub2 · Cited by 33 · see citing works
Management of mood and anxiety disorders in patients receiving opioid agonist therapy: Review and meta-analysis
Hassan, A. N., Howe, A. S., Samokhvalov, A. V., Foll, B. L., & George, T. P. (2017) · American Journal on Addictions · doi:10.1111/ajad.12581 · Cited by 32 · see citing works
Cerebral metabolism and mood in remitted opiate dependence
GALYNKER, I. I., Eisenberg, D. P., Matochik, J. A., Gertmenian-King, E., Cohen, L. J., Kimes, A. S., Contoreggi, C. S., Kurian, V., Monique Ernst, D., Rosenthal, R. N., et al. (2007) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2007.03.015 · Cited by 31 · see citing works
Interim buprenorphine treatment during delays to comprehensive treatment: Changes in psychiatric symptoms.
Streck, J. M., Ochalek, T. A., Badger, G. J., & Sigmon, S. C. (2018) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000199 · Cited by 26 · see citing works
Buprenorphine as a Treatment for Major Depression and Opioid Use Disorder
Namchuk, A. B., Lucki, I., & Browne, C. A. (2022) · Advances in Drug and Alcohol Research · doi:10.3389/adar.2022.10254 · Cited by 26 · see citing works
Predictors for Dropping-Out From Methadone Maintenance Therapy Programs Among Heroin Users in Southern Taiwan
Lin, H., Chen, K.-Y., Wang, P., Yen, C., Wu, H., Yeh, Y., Yeh, Y.-C., Chung, K.-S., & Chang, H. (2013) · Substance Use & Misuse · doi:10.3109/10826084.2012.749411 · Cited by 25 · see citing works
Bidirectional relationship between heroin addiction and depression: Behavioural and neural studies
Moustafa, A. A., Tindle, R., Cashel, S., Parkes, D., Mohamed, E., & Hamza, E. A. (2020) · Current Psychology · doi:10.1007/s12144-020-01032-4 · Cited by 24 · see citing works
Patterns of psychological distress related to regular methamphetamine and opioid use
Darke, S. G., Torok, M. H., McKetin, R., Kaye, S. S., & Ross, J. E. (2011) · Addiction Research & Theory · doi:10.3109/16066351003695631 · Cited by 24 · see citing works
Changes in mental health during opiate replacement therapy: A systematic review
Fingleton, N. A., Matheson, C., & Jaffray, M. (2014) · Drugs Education Prevention and Policy · doi:10.3109/09687637.2014.899986 · Cited by 23 · see citing works
Medications between psychiatric and addictive disorders
Lalanne, L., Lutz, P.-É., Trojak, B., Lang, J.-P., Kieffer, B. L., & Bacon, É. (2015) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.10.009 · Cited by 21 · see citing works
A meta-analysis of the potential antidepressant effects of buprenorphine versus placebo as an adjunctive pharmacotherapy for treatment-resistant depression
Dinoff, A., Lynch, S. T., Sekhri, N. K., & Klepacz, L. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.03.089 · Cited by 20 · see citing works
Effects of opioid rotation to buprenorphine/naloxone on pain, pain thresholds, pain tolerance, and quality of life in patients with chronic pain and opioid use disorder
Veldman, S. E., van Beek, M., van Rijswijk, S. M., Ellerbroek, H., Timmerman, H., van der Wal, S., Steegers, M. A. H., & Schellekens, A. (2021) · Pain · doi:10.1097/j.pain.0000000000002462 · Cited by 19 · see citing works
Non-Fatal Opioid Overdose and Major Depression among Street-Recruited Young Heroin Users
Chahua, M., Sordo, L., Barrio, G., Domingo‐Salvany, A., Brugal, M. T., Molist, G., de la Fuente, L., Bravo, M. J., & and ITINERE Project Group (2013) · European Addiction Research · doi:10.1159/000346787 · Cited by 19 · see citing works
The Overlap of Sleep Disturbance and Depression in Primary Care Patients Treated with Buprenorphine
Garnaat, S. L., Weisberg, R. B., Uebelacker, L. A., Herman, D. S., Bailey, G. L., Anderson, B. J., Sharkey, K. M., & Stein, M. D. (2017) · Substance Abuse · doi:10.1080/08897077.2017.1361498 · Cited by 19 · see citing works
Depression history as a predictor of outcomes during buprenorphine-naloxone treatment of prescription opioid use disorder
Peckham, A., Griffin, M. L., McHugh, R. K., & Weiss, R. D. (2020) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2020.108122 · Cited by 19 · see citing works
Substance Abuse and Depression
Renner, J. A., Baxter, J., Suzuki, J., & Ciraulo, D. A. (2010) · Humana Press eBooks · doi:10.1007/978-1-60327-435-7_6 · Cited by 17 · see citing works
The Role of Opiates in Social Pain and Suicidal Behavior
Nobile, B., Lutz, P.-E., Olie, E., & Courtet, P. (2020) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2020_167 · Cited by 24 · see citing works
I feel good? Anhedonia might not mean “without pleasure” for people treated for opioid use disorder.
Stull, S. W., Bertz, J. W., Panlilio, L. V., Kowalczyk, W. J., Phillips, K. A., Moran, L. M., Lin, J., Vahabzadeh, M., Finan, P. H., Preston, K. L., et al. (2021) · Journal of Abnormal Psychology · doi:10.1037/abn0000674 · Cited by 14 · see citing works
Effects of Buprenorphine/Naloxone and Methadone on Depressive Symptoms in People with Prescription Opioid Use Disorder: A Pragmatic Randomised Controlled Trial
Bastien, G., McAnulty, C., Ledjiar, O., Socias, M. E., Foll, B. L., Lim, R., Hassan, A. N., Brissette, S., Marsan, S., Talbot, A., et al. (2022) · The Canadian Journal of Psychiatry · doi:10.1177/07067437221145013 · Cited by 14 · see citing works
Opioidergic Agents as Antidepressants: Rationale and Promise
Saxena, P. P., & Bodkin, J. A. (2018) · CNS Drugs · doi:10.1007/s40263-018-0584-7 · Cited by 13 · see citing works
Quality of life and associated factors of heroin‐dependent patients receiving methadone and buprenorphine maintenance treatment
Chang, H., Huang, M., Fang, S., & Lin, S. (2023) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12402 · Cited by 9 · see citing works
Beneficial Effects of Opioid Rotation to Buprenorphine/Naloxone on Opioid Misuse, Craving, Mental Health, and Pain Control in Chronic Non-Cancer Pain Patients with Opioid Use Disorder
Schellekens, A., Veldman, S. E., Suranto, E. S. D., van Rijswijk, S. M., van der Wal, S. E. I., Schene, A. H., & Beek, M. H. C. T. V. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10163727 · Cited by 9 · see citing works
Effects of Interim Buprenorphine Treatment for opioid use disorder among emerging adults
Peck, K. R., Ochalek, T. A., Badger, G. J., & Sigmon, S. C. (2020) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2020.107879 · Cited by 9 · see citing works
Longitudinal study of impact of medication for opioid use disorder on Hamilton Depression Rating Scale
Wang, K., DiChiacchio, T., Fang, W. L., Lander, L. R., Feinberg, J., Xie, C., Winstanley, E. L., & Piamjariyakul, U. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.10.018 · Cited by 8 · see citing works
The Effectiveness of Matrix Interventions in Improving Methadone Treatment
Eghbali, H., Zare, M., Bakhtiari, A., Monirpour, N., & Ganjali, A. (2013) · international journal high risk behaviors & addiction · doi:10.5812/ijhrba.7906 · Cited by 7 · see citing works
Within-subject evaluation of interim buprenorphine treatment during waitlist delays
Oleskowicz, T. N., Ochalek, T. A., Peck, K. R., Badger, G. J., & Sigmon, S. C. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.108532 · Cited by 6 · see citing works
Eficacia y manejo clínico de la buprenorfina
Roncero, C., Sáez‐Francàs, N., Cervelló, X. C., & Casas, M. (2008) · Trastornos Adictivos · doi:10.1016/s1575-0973(08)74549-5 · Cited by 6 · see citing works
The Effectiveness of Methadone Maintenance Treatment in the Reduction of Anxiety and Depression Among Drug-Related Prisoners
Momtaz, A., Noorzadeh, M., Bargard, M. S., Saki, S., & Beheshti, S. T. S. (2014) · Jundishapur Journal of Health Sciences · doi:10.5812/jjhs.23475 · Cited by 6 · see citing works
Impact of Co-Occurring Psychiatric Comorbidities and Substance Use Disorders on Outcomes in Adolescents and Young Adults with Opioid Use Disorder: A Retrospective Cohort Study
Liu, L., McKnight, E. R., Bonny, A. E., Tao, H., Zhao, P., & Nahata, M. C. (2025) · Pharmaceuticals · doi:10.3390/ph18050609 · Cited by 5 · see citing works
Impact of Depressive Symptom Severity on Buprenorphine/Naloxone and Methadone Outcomes in People With Prescription-Type Opioid Use Disorder: Results From a Pragmatic Randomized Controlled Trial
Bastien, G., Abboud, A., McAnulty, C., Elkrief, L., Ledjiar, O., Socias, M. E., Foll, B. L., Bahji, A., Brissette, S., Marsan, S., et al. (2024) · Journal of Dual Diagnosis · doi:10.1080/15504263.2024.2329267 · Cited by 5 · see citing works
Correlates of Depressive Symptoms among Alcohol‐Using Methadone Maintained Adults
Nyamathi, A., Albarrán, C. R., Branson, C. M., Marfisee, M., Khalilifard, F., & LEAKE, B. D. (2012) · American Journal on Addictions · doi:10.1111/j.1521-0391.2012.00300.x · Cited by 5 · see citing works
Medication Treatments for Opioid Use Disorder: What Is the Impact on Mood and Mood Disorders?
Hassan, A. N., & Nunes, E. V. (2018) · Current Addiction Reports · doi:10.1007/s40429-018-0215-x · Cited by 5 · see citing works
Patient Characteristics Associated with Opioid Abstinence after Participation in a Trial of Buprenorphine versus Injectable Naltrexone
Greiner, M. G., Shulman, M., Scodes, J. M., Choo, T.-H. J., Pavlicová, M., Opara, O., Campbell, A. N. C., Novo, P., Fishman, M. J., Lee, J. D., et al. (2022) · Substance Use & Misuse · doi:10.1080/10826084.2022.2112230 · Cited by 4 · see citing works
COMPARISON OF THE EFFECTIVENESS OF COGNITIVE-BEHAVIOR THERAPY, METHADONE THERAPY, AND THE COMBINATION METHOD ON REDUCING DEPRESSION IN ADDICTS
Kashani, F. L., Mojtabaei, M., & Alimehdi, M. (2014) · Knowledge & Research in Applied Psychology · Cited by 4 · see citing works
Predictors of Relapse in Patients with Opioid Addiction during Buprenorphine–Naloxone Maintenance Treatment
Canan, F. (2015) · Addiction & Addictive Disorders · doi:10.24966/aad-7276/100005 · Cited by 3 · see citing works
Pharmacotherapy of Dual Disorders
Soyka, M., & Grunze, H. (2014) · Springer eBooks · doi:10.1007/978-3-642-45375-5_19 · Cited by 2 · see citing works
The Impact of Prolonged Exposure Therapy on Posttraumatic Stress Disorder Symptom Clusters in Adults Maintained on Medications for Opioid Use Disorder
Giannini, J., Badger, G. J., Cole, R., & Peck, K. R. (2025) · Clinical Psychology & Psychotherapy · doi:10.1002/cpp.70199 · Cited by 1 · see citing works
Investigating the Effects of Buprenorphine Treatment on Depression Symptoms Among Adults with Opioid Use Disorder: A Scoping Review
Votaw, V. R., Rosen, R. S., Peckham, A., London, Z., Philpotts, L. L., Weiss, R. D., McHugh, R. K., & Streck, J. M. (2026) · Journal of Dual Diagnosis · doi:10.1080/15504263.2026.2638194 · Cited by 1 · see citing works
Qualitative Study of Factors Affecting Adherence to Treatment in Substance-Dependent Individuals with Maintenance Treatment in Isfahan
khaghani, F., (خوراسگان), د. آ. ا. و. ا., Torkan, H., (خوراسگان), د. آ. ا. و. ا., Yousefi, Z., & (خوراسگان), د. آ. ا. و. ا. (2020) · فصلنامه علمی و پژوهشی اعتیادپژوهی · doi:10.29252/etiadpajohi.14.56.59 · Cited by 1 · see citing works
The effect of brief behavioral activation treatment on symptoms of depression, mental health and quality of life among the patients with opioid abuse
Hasani, J., Parhoon, H., & Momeni‎, K. (2015) · Majallah-i dānishgāh-i ̒ulūm-i pizishkī-i Kirmānshāh · doi:10.22110/jkums.v19i2.2209
Buprenorphine as a psychoactive drug
Maremmani, I., Pacini, M., & Dole, V. P. (2006)
Impact of opioid agonists on mental health in substitution treatment for opioid use disorder: A systematic review and Bayesian network meta-analysis of randomized clinical trialsPreprint
Zadeh, E. M., Ziafat, K., Yazdani, K., Mamdouh, M., Wong, J. S. H., Modabbernia, A., Blanken, P., Verthein, U., Schütz, C. G., Jang, K. L., et al. (2020) · medRxiv · doi:10.1101/2020.07.04.20146506
Trầm cảm ở người bệnh điều trị Methadone và Buprenorphine tại một số tỉnh miền núi phía Bắc Việt Nam: tỷ lệ và các yếu tố liên quan
Luân, P. T., Anh, V. M., Diệp, N. B., Trang, N. T., Tâm, N. T., Cảnh, H. Đ., & Giang, L. M. (2021) · Tạp chí Nghiên cứu Y học · doi:10.52852/tcncyh.v140i4.143
Current awareness in human psychopharmacology
(2005) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.636
Depression and Suicidal Ideation among Patients Receiving Opioid Maintenance Treatments Considering Cognitive Flexibility
Rajabpour, M., Mirmohammadkhani, M., & Paknazar, F. (2023) · Iranian Journal of Psychiatry · doi:10.18502/ijps.v18i3.13005
Potential Role for Buprenorphine in the Management of Comorbid Depression Among People with Chronic Pain and Long-Term Opioid Therapy Dependence
Manhapra, A., Rosenheck, R. A., & Becker, W. C. (2024) · doi:10.1093/9780197675250.003.0009
Opioid agents for treatment-resistant depression
Serafini, G., Adavastro, G., Canepa, G., Amerio, A., Aguglia, A., & Amore, M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824067-0.00016-5
Mood disruption in heroin abstinence : mechanisms and gene discovery
Ayrancı, G. (2015) · doi:10.70675/a956874cz8192z4eb4zb9dez3ceb46a28053
Psychiatric Comorbidity in Research on Medications for Opioid Use Disorder
Ameral, V., Falcón, A. K., Wolkowicz, N. R., Patterson, J. A., & MacLean, R. R. (2026) · The Journal of Nervous and Mental Disease · doi:10.1097/nmd.0000000000001883

Síntomas depresivos durante el mantenimiento con buprenorfina frente a metadona: hallazgos de un ensayo controlado distribuido al azar en la dependencia de opioides
Dean, A. J., Bell, J. R., Christie, M. J., & Mattick, R. P. (2005) · European psychiatry (Ed Española) · doi:10.1017/s1134066500003441
Effects of Buprenorphine/Naloxone and Methadone on Depressive Symptoms in People with Prescription Opioid Use Disorder: A Pragmatic Randomised Controlled Trial
Bastien, G., McAnulty, C., Ledjiar, O., Socias, M. E., Foll, B. L., Lim, R., Hassan, A. N., Brissette, S., Marsan, S., Talbot, A., et al. (2022) · The Canadian Journal of Psychiatry · doi:10.1177/07067437221145013 · Cited by 14 · see citing works
Efficacy of buprenorphine in the treatment of co- occurring opioid use disorder and depression: a systematic review and exploratory meta-analysis
Παπαοικονόμου, Δ. Α. (2026) · Aristotle University of Thessaloniki · doi:10.26262/heal.auth.ir.373788
Depression Predicts Higher Rates of Heroin Use on Desipramine with Buprenorphine than with Methadone
Kosten, T. R., Falcioni, J., Oliveto, A. H., & Feingold, A. (2004) · American Journal on Addictions · doi:10.1080/10550490490435966 · Cited by 19 · see citing works
Investigating the Effects of Buprenorphine Treatment on Depression Symptoms Among Adults with Opioid Use Disorder: A Scoping Review
Votaw, V. R., Rosen, R. S., Peckham, A., London, Z., Philpotts, L. L., Weiss, R. D., McHugh, R. K., & Streck, J. M. (2026) · Journal of Dual Diagnosis · doi:10.1080/15504263.2026.2638194 · Cited by 1 · see citing works

Authors: Dean, A. J., Bell, J., Christie, M. J., & Mattick, R. P.
Affiliations: The University of Sydney (AU)
UNSW Sydney (AU)
Corresponding author: Dean, Angela J.
ORCID: Dean, Angela J.
Bell, James
Christie, Macdonald J.
Venue: European Psychiatry
Publisher: Cambridge University Press (CUP)
Published: 2004-12
Volume: 19
Issue: 8
Pages: 510-513
ISSN: 0924-9338 (ISSN-L)
1778-3585
DOI: 10.1016/j.eurpsy.2004.09.002
OpenAlex: W2068749862
Cited by: 78
References: 29
Citations by year: 2026: 2 · 2025: 2 · 2024: 2 · 2023: 3 · 2022: 4 · 2021: 7 · 2020: 8 · 2018: 4 · 2017: 2 · 2016: 1 · 2015: 4 · 2014: 6 · 2013: 6 · 2012: 3
FWCI: 4.07
Type: journal article
Language: en
Open access: closed
Licence: www.cambridge.org/core/terms (unspecified, 5615 d)
Locations: European Psychiatry (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
Keywords: buprenorphine, methadone maintenance treatment, opioid use disorder, heroin addiction, depressive symptoms, antidepressant effects, opioid substitution therapy, Beck Depression Inventory
MeSH terms: Adult, Buprenorphine, Depression, Female, Humans, Male, Methadone, Narcotic Antagonists, Opioid-Related Disorders, Narcotics, Surveys and Questionnaires, Severity of Illness Index

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Depressive symptoms during buprenorphine vs. methadone maintenance: Findings from a randomised, controlled trial in opioid dependence

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks